Affibody Progresses Lead Asset To Phase II in Uveitis
IL-17 blocker izokibep targets autoimmune diseases
Executive Summary
The FDA has cleared the novel interleukin-17 blocker izokibep (ABY-035) to proceed to Phase II clinical development in non-infectious intermediate, posterior and pan-uveitis.